Risk for New onset of Depression in Perimenopausal Women
Risk for New onset of Depression in Perimenopausal Women
批准号:
7431076
负责人:
DANIEL William CRAMER
金额:
$50.06万
依托单位国家:
美国
项目类别:
财政年份:
2004
资助国家:
美国
项目状态:
已结题
起止时间:
2004-05-13 至 2009-11-30
关键词:
AdolescenceAgeAge at MenarcheAge-YearsAppendixAttentionAttenuatedBlood specimenClassificationClimactericClinicalClinical assessmentsDataData SetDepressed moodDepressive disorderDysthymic DisorderEconomicsEndocrineEnsureEpidemiologic StudiesEstradiolEventFollicle Stimulating HormoneGeneral PopulationHormone replacement therapyIncidenceInterviewInvestigationLifeLongevityMajor Depressive DisorderMeasurementMeasuresMedical HistoryMenopauseMenstrual cycleMenstruationMental DepressionMental disordersMinorityMood DisordersMoodsMorbidity - disease rateNatureNeurotic DisordersParticipantPerimenopausePersonsPopulationPositioning AttributePremenopauseProspective StudiesPsychiatric DiagnosisPsychosocial StressPublic HealthPublishingRecording of previous eventsRecruitment ActivityRecurrenceRiskRisk FactorsSamplingSerumSeveritiesSignal TransductionSocial supportStructureStudy SubjectSurveysSymptomsTimeVasomotorWomanagedbasecohortdepressive symptomsdesigndisturbance in affectearly onsethormone therapyindexingmenminor depressive disorderproliferative phase Menstrual cycleprospectivereproductivereproductive hormoneresilience
中文摘要
描述(由申请人提供):几项流行病学研究表明,与男性相比,女性在青春期开始并持续一生的抑郁风险要大得多。此外,女性抑郁症的年龄特异性发病率在生育年龄后期达到高峰。然而,对于没有情绪障碍病史的女性来说,围绝经期在多大程度上代表了新发抑郁症的更大风险还有待确定。哈佛情绪和周期研究(HSMC)是一项基于人群的绝经前老年妇女的前瞻性研究,由于对精神疾病发病率和月经周期随时间变化的严格系统评估,因此非常适合调查这种关联。在这项研究中,大约1000名绝经前妇女(有或没有终生抑郁史)接受了为期36个月的随访,每半年进行一次精神评估、病史访谈和早期卵泡期血液标本,以测量血清中的生殖激素。我们发表的研究结果表明:1)初潮年龄和生育早期的其他事件与抑郁症的风险相关;2)与没有抑郁症史的女性相比,有重度抑郁症史的女性(尤其是那些在临近绝经期时抑郁症状更严重的女性)发生月经周期变化的风险更大,这些变化与那些预示着提前过渡到绝经期的女性相一致。3)卵泡期早期,随着绝经期的临近,抑郁女性的卵泡刺激素和黄体生成素水平高于非抑郁女性,雌二醇水平低于非抑郁女性。
英文摘要
DESCRIPTION (provided by applicant): Several epidemiological studies have shown that women, compared to men, are at a substantially greater risk of depression beginning in adolescence and continuing through their entire life. In addition, the age-specific incidence of depression in women peaks during the late reproductive years. However, the extent to which the perimenopause represents a time of greater risk for new onset of depression in women with no history of mood disorder is yet to be determined. The Harvard Study of Moods and Cycles (HSMC), a population-based prospective study of late premenopausal aged women, is uniquely suited to investigate this association because of the rigorous systematic assessment of psychiatric morbidity and menstrual cycle changes over time. In this study, approximately 1000 premenopausal women with and without a lifetime history of depression were followed over 36 months with semi-annual psychiatric assessments, medical history interviews, and early follicular phase blood specimens to measure reproductive hormones in serum. Our published results have shown that 1) age at menarche and other events in early reproductive life are associated with risk for depression, 2) women with a lifetime history of major depression (particularly those with more severe depressive symptoms proximate to the perimenopause) are at a greater risk of developing menstrual cycle changes consistent with those that signal an earlier transition to the perimenopause compared to women with no depression history, and 3) early follicular phase FSH and LH are higher, and estradiol levels are lower in depressed compared to non-depressed late reproductive aged women as they move toward the climacteric.
Having carefully gathered prospective data on psychiatric disorders and changes in menstruation, we now have a unique opportunity to evaluate the impact of the perimenopausal transition on risk of first onset of mood disturbance. In this current submission, we plan to include approximately 500 women from the original HSMC with no lifetime history of major depression, and will enrich this sample with an additional 200 largely minority women from the general population. Our preliminary data suggest that an earlier onset to the perimenopausal transition is associated with a 3-fold risk of new onset of major depression in women with no prior history of depressive disorder. Furthermore, it appears that initiation of hormonal therapy to treat menstrual cycle changes, irregularities, or somatic symptoms attenuates this increased risk of a first onset of depressive episode. We plan to better assess the effect of onset to the perimenopause on the risk for new onset of mood disturbance independent of past depression history that clearly influences the risk of recurrent episodes. The present project is designed to confirm and expand upon these preliminary findings by using structured clinical interviews for accurate psychiatric diagnoses, and comprehensive assessments of clinical symptoms at the time of the menopausal transition.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Mucins and immune cell interactions in ovarian cancer pathogenesis & progression
-
批准号:8956011
-
项目类别:
-
资助金额:$105.29万
-
财政年份:2016
-
负责人:DANIEL William CRAMER
-
依托单位:
Mucins and immune cell interactions in ovarian cancer pathogenesis & progression
-
批准号:10356028
-
项目类别:
-
资助金额:$89.29万
-
财政年份:2016
-
负责人:DANIEL William CRAMER
-
依托单位:
Mucins and immune cell interactions in ovarian cancer pathogenesis & progression
-
批准号:9210070
-
项目类别:
-
资助金额:$103.13万
-
财政年份:2016
-
负责人:DANIEL William CRAMER
-
依托单位:
Screening and Risk Biomarkers for Ovarian Cancer in EPIC Specimens
-
批准号:8295543
-
项目类别:
-
资助金额:$56.69万
-
财政年份:2012
-
负责人:DANIEL William CRAMER
-
依托单位:
Screening and Risk Biomarkers for Ovarian Cancer in EPIC Specimens
-
批准号:8448623
-
项目类别:
-
资助金额:$51.44万
-
财政年份:2012
-
负责人:DANIEL William CRAMER
-
依托单位:
Screening and Risk Biomarkers for Ovarian Cancer in EPIC Specimens
-
批准号:8628791
-
项目类别:
-
资助金额:$47.42万
-
财政年份:2012
-
负责人:DANIEL William CRAMER
-
依托单位:
MUC-1 related cancer immunity: determinants and predictive significance
-
批准号:7455073
-
项目类别:
-
资助金额:$27.88万
-
财政年份:2006
-
负责人:DANIEL William CRAMER
-
依托单位:
MUC-1 related cancer immunity: determinants and predictive significance
-
批准号:7278226
-
项目类别:
-
资助金额:$28.33万
-
财政年份:2006
-
负责人:DANIEL William CRAMER
-
依托单位:
MUC-1 related cancer immunity: determinants and predictive significance
-
批准号:7644003
-
项目类别:
-
资助金额:$27.42万
-
财政年份:2006
-
负责人:DANIEL William CRAMER
-
依托单位:
MUC-1 related cancer immunity: determinants and predictive significance
-
批准号:7136364
-
项目类别:
-
资助金额:$29.18万
-
财政年份:2006
-
负责人:DANIEL William CRAMER
-
依托单位:
Risk for New onset of Depression in Perimenopausal Women
-
批准号:6894243
-
项目类别:
-
资助金额:$51.78万
-
财政年份:2004
-
负责人:DANIEL William CRAMER
-
依托单位:
Administration, Communication, Evaluation, and Planning
-
批准号:6991039
-
项目类别:
-
资助金额:$22.48万
-
财政年份:2004
-
负责人:DANIEL William CRAMER
-
依托单位:
Risk for New onset of Depression in Perimenopausal Women
-
批准号:7476262
-
项目类别:
-
资助金额:$50.47万
-
财政年份:2004
-
负责人:DANIEL William CRAMER
-
依托单位:
Dana-Farber/Harvard Cancer Center Ovarian Cancer SPORE
-
批准号:7280829
-
项目类别:
-
资助金额:$227.88万
-
财政年份:2004
-
负责人:DANIEL William CRAMER
-
依托单位:
Dana-Farber/Harvard Cancer Center Ovarian Cancer SPORE
-
批准号:8117918
-
项目类别:
-
资助金额:$50.0万
-
财政年份:2004
-
负责人:DANIEL William CRAMER
-
依托单位:
Dana-Farber/Harvard Cancer Center Ovarian Cancer SPORE
-
批准号:7499084
-
项目类别:
-
资助金额:$217.62万
-
财政年份:2004
-
负责人:DANIEL William CRAMER
-
依托单位:
Dana-Farber/Harvard Cancer Center Ovarian Cancer SPORE
-
批准号:7933129
-
项目类别:
-
资助金额:$119.32万
-
财政年份:2004
-
负责人:DANIEL William CRAMER
-
依托单位:
Dana-Farber/Harvard Cancer Center Ovarian Cancer SPORE
-
批准号:6920071
-
项目类别:
-
资助金额:$240.33万
-
财政年份:2004
-
负责人:DANIEL William CRAMER
-
依托单位:
Dana-Farber/Harvard Cancer Center Ovarian Cancer SPORE
-
批准号:7499956
-
项目类别:
-
资助金额:$8.75万
-
财政年份:2004
-
负责人:DANIEL William CRAMER
-
依托单位:
Risk for New onset of Depression in Perimenopausal Women
-
批准号:7536380
-
项目类别:
-
资助金额:$35.62万
-
财政年份:2004
-
负责人:DANIEL William CRAMER
-
依托单位:
国内基金
海外基金
登录
查看更多内容
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
-
批准号:JCZRLH202601523
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
-
批准号:JCZRQN202500010
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:
-
依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
-
批准号:2025JJ70209
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:雷芬芳
-
依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
-
批准号:--
-
项目类别:面上项目
-
资助金额:--
-
批准年份:2024
-
负责人:万荣
-
依托单位:
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
-
批准号:2023JJ50274
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2023
-
负责人:贺志明
-
依托单位:
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
-
批准号:--
-
项目类别:地区科学基金项目
-
资助金额:33万元
-
批准年份:2022
-
负责人:都义日
-
依托单位:
补肾健脾祛瘀方调控AGE/RAGE信号通路在再生障碍性贫血骨髓间充质干细胞功能受损的作用与机制研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2022
-
负责人:叶宝东
-
依托单位:
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2022
-
负责人:于海兵
-
依托单位:
围绕GLP1-Arginine-AGE/RAGE轴构建探针组学方法探索大柴胡汤异病同治的效应机制
-
批准号:81973577
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2019
-
负责人:辛贵忠
-
依托单位:
AGE/RAGE通路microRNA编码基因多态性与2型糖尿病并发冠心病的关联研究
-
批准号:81602908
-
项目类别:青年科学基金项目
-
资助金额:18.0万元
-
批准年份:2016
-
负责人:刘括
-
依托单位: